Full Title: Antisense Oligonucleotide Purification Process: Successes and Challenges During Scale-up
Presented by Robert Gronke, Ph.D., Senior Principal Scientist, Technical Development, Biogen
Recently, our first full scale GMP batch for an antisense oligonucleotide was manufactured in the newly built synthesis suite at Biogen. A four-step purification process was then carried out in the existing flexible volume manufacturing facility that, up until this point, has been used for manufacturing Biogen’s protein-based parenterals. This was our first test case to demonstrate that Biogen can manufacture ASOs safely, at scale, and achieve high purity and yield. Results are presented on the scalability of the ASO process from bench to GMP scale, highlighting successes and challenges faced with scale-up of the downstream ASO process.
Followed by an industry perspective presented by Thomas Müller-Späth, Ph.D, CTO at YMC ChromaCon